Journal article

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia

Masa Lasica, Abbey Willcox, Kate Burbury, David M Ross, Susan Branford, Jason Butler, Robin Filshie, Henry Januszewicz, David Joske, Anthony Mills, David Simpson, Constantine Tam, Kerry Taylor, Anne-Marie Watson, Max Wolf, Andrew Grigg

Leukemia & Lymphoma | TAYLOR & FRANCIS LTD | Published : 2019

Abstract

The management of CML in pregnancy is challenging with the need to balance disease control against potential teratogenic effects of TKI therapy. In this multi-center case-cohort study of 16 women in chronic phase, CML ceased TKI treatment pre- or post-conception during their first pregnancy. Thirteen patients were on imatinib; 9 ceased their TKI prior to conception and 7 ceased at pregnancy confirmation. Twelve patients had achieved either MMR or better at time of TKI cessation. Eleven women lost MMR during pregnancy and two patients lost CHR. Fourteen women reestablished MMR on TKI recommenced. The depth molecular response prior to conception appeared to correlate well with restoration of d..

View full abstract